TP53 mutations can have a significant impact on the prognosis of diseases like chronic lymphocytic leukemia, but their effect ...

New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important ...

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical ...

Adult patients with moderate to severe hand eczema with previous treatment failure or in whom topical corticosteroids are ...

Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, reflects on the impact of HER2 identification on the breast cancer ...

Mother-to-child transmission often led to pretreatment drug resistance and acquired drug resistance in children living with ...

An expert discusses how long-term safety considerations are evaluated through clinical trial data and postmarketing ...

New data highlight efficacy, safety, and time off treatment with as-needed ruxolitinib cream in pediatric atopic dermatitis.

Rebecca Chacko, MD, discussed exciting advancements in breast cancer care and the future role of emerging therapeutic strategies for early recurrence detection, as part of her panelist role at the ...

The FDA’s approval of linvoseltamab for adults with heavily pretreated relapsed/refractory multiple myeloma marks a significant advance, with Sundar Jagannath, MBBS, emphasizing its high response ...

State governments must have budgetary and regulatory flexibility to support health care innovation, says Sen. Vincent Polistina (R, New Jersey).

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.